World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials
Related Experiment Videos
M Boers1, P Tugwell, D T Felson
1Department of Internal Medicine/Rheumatology, University Hospital Maastricht, The Netherlands.
The Journal of Rheumatology. Supplement
|September 1, 1994
Abstract:
The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.